Patents Assigned to Pharming
  • Publication number: 20230118307
    Abstract: New uses of a triple agonist are disclosed. A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, or conjugates thereof exhibits an activity of preventing and/or treating lung diseases. A use of the triple agonist or a conjugate thereof as a preventive and/or therapeutic agent for lung disease, and compositions and methods for preventing and/or treating lung cancer employing the triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or conjugates are disclosed.
    Type: Application
    Filed: November 20, 2020
    Publication date: April 20, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Seon Myeong LEE, Jong Suk LEE, Jung Kuk KIM, Sang Hyun LEE, Euh Lim OH, Hyo Sang JO, Eun Jin PARK, Chong Yoon LIM
  • Publication number: 20230103271
    Abstract: Provided is a novel method for preparing a long-acting drug conjugate and a long-acting drug conjugate prepared using the method.
    Type: Application
    Filed: July 18, 2019
    Publication date: March 30, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Cheongbyeol SHIN, Dooseo JANG, Ji Hye MOON, Dong Hyun KIM, Ji Eun LEE
  • Publication number: 20230101131
    Abstract: The present invention relates to a crystalline form of a phenyl carbamate derivative compound and a use thereof, and more particularly, to a more thermodynamically stable crystal, i.e., a Pattern 1 crystalline form, and a preparation method thereof. Amorphous and crystalline forms were prepared using various solvents, and among these, a thermodynamically stable Pattern 1 crystalline form and a pharmaceutical use of this crystalline form are provided.
    Type: Application
    Filed: June 10, 2022
    Publication date: March 30, 2023
    Applicant: BIO-PHARM SOLUTIONS CO., LTD.
    Inventor: Yong Moon CHOI
  • Publication number: 20230090790
    Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. The GLP-2 derivative or a conjugate thereof are useful in preventing or treating one or more diseases selected from intestinal disease, intestinal injury, or gastrosia. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
    Type: Application
    Filed: November 2, 2022
    Publication date: March 23, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jaehyuk CHOI, Min Young KIM, In Young CHOI, Sung Youb JUNG
  • Patent number: 11603346
    Abstract: The present invention relates to polyethylene glycol derivatives and use thereof.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: March 14, 2023
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Dae Jin Kim, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
  • Patent number: 11591333
    Abstract: The present invention provides a method for preparing a pyrrolopyrimidine compound and application thereof. Specifically, the present invention provides a compound represented by formula I or pharmaceutically-acceptable salts thereof, a pharmaceutical composition containing the compound or its salts, and a method for preparing the pharmaceutical composition and an application of the pharmaceutical composition as an immunosuppressive drug.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: February 28, 2023
    Assignees: CINAKATE PHARM TECH (SHANGHAI) CO., LTD., CINKATE PHARMACEUTICAL INTERMEDIATES CO., LTD.
    Inventors: Na Liu, Lixia Bao, Zhepeng Wei, Yufeng Zhou, Bin Rong, Lihui Zhao, Fei Xiao
  • Patent number: 11591409
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 28, 2023
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • Patent number: 11591302
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: February 28, 2023
    Assignee: GEISTLICH PHARM A AG
    Inventors: Rolf W. Pfirrmann, Hanns Moehler, Thomas Mueller
  • Publication number: 20230058432
    Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.
    Type: Application
    Filed: January 22, 2021
    Publication date: February 23, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Bo Sik KIM, Hyuk Jun CHO, Ho Taek IM, Yong II KIM
  • Patent number: 11583495
    Abstract: The present disclosure relates to a method for delivering a mucoadhesive composition to the oral cavity of a subject. The mucoadhesive composition comprises one or more active agents, a mucoadhesive polymer, and water. The present disclosure is further related to a method for treating a disease, disorder, or condition, such as pharyngitis, aphthous stomatitis (canker sore), bacterial infection, radiation-induced mucositis, fibromyalgia, and diabetes, comprising administering the mucoadhesive composition to the oral cavity of a subject. The present disclosure is also related a mucoadhesive composition comprising one or more active agents, a mucoadhesive polymer, and water.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: February 21, 2023
    Assignee: Northriver Pharm, LLC
    Inventor: William L. Pridgen
  • Publication number: 20230033410
    Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 2, 2023
    Applicant: HANMI PHARM. CO.,LTD.
    Inventors: Seung Hun CHANG, Kwang Young LEE, Jae Ho KIM, Hung Hyun CHO, Yong ll KIM
  • Publication number: 20230000950
    Abstract: A composition containing a glucagon derivative and a GLP-1 and GIP receptor dual agonist, and uses thereof are disclosed. The glucagon derivative comprises an amino acid sequence of the formula 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-F-X23-X24-WL-X27-X28-X29-X30 (Formula 1). The composition is useful in preventing or treating metabolic syndrome.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 5, 2023
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jung Kuk KIM, Jong Suk LEE, A Ram LEE, Joo Young DONG
  • Patent number: 11534435
    Abstract: This present invention relates to a drug carrier comprising a polymer of ?-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal, and a method for preparing the same. It can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: December 27, 2022
    Assignee: Hainan Poly Pharm Co., Ltd.
    Inventors: Youqing Shen, Quan Zhou, Changhuo Xu, Jiajia Xiang
  • Patent number: 11530249
    Abstract: A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: December 20, 2022
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jaehyuk Choi, Min Young Kim, In Young Choi, Sung Youb Jung
  • Publication number: 20220378790
    Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.
    Type: Application
    Filed: October 23, 2020
    Publication date: December 1, 2022
    Applicant: Hanmi Pharm Co., Ltd.
    Inventors: Young II Kim, Taek Kwan Kwon, Ho Taek Im, Yong II Kim
  • Publication number: 20220380437
    Abstract: A physiologically active polypeptide-immunoglobulin Fc fragment conjugate and a method for making the conjugate are disclosed. The conjugate contains a physiologically active polypeptide linked via a non-peptidyl linker to an immunoglobulin Fc fragment having an FcRn-binding region and maintains the intrinsic binding affinity of the immunoglobulin Fc fragment. A method of maintaining the intrinsic binding affinity of the conjugate for FcRn, and a composition containing the conjugate, which maintains the intrinsic binding affinity of the immunoglobulin Fc fragment for FcRn are also disclosed.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Sang Youn HWANG, Jong Soo Lee, Sung Hee Hong, In Young Choi, Sung Youb Jung, Se Chang Kwon
  • Publication number: 20220362347
    Abstract: Composition including GLP-2 or a long-acting conjugate thereof and uses thereof are disclosed. The composition including GLP-2 or a long-acting conjugate thereof is useful for preventing or treating metabolic bone diseases.
    Type: Application
    Filed: December 24, 2020
    Publication date: November 17, 2022
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Jae Hyuk CHOI, Jin Bong LEE, Sang Hyun LEE, Sang Don LEE, Min Young KIM
  • Publication number: 20220362356
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, comprising snake venom derived from Agkistrodon piscivorus piscivorus or Naja melanoleuca, which are types of snakes, an extract thereof, or a fraction thereof; a quasi-drug composition; a food composition; a cosmetic composition; and a method of treating rheumatoid arthritis by using the composition. The snake venom derived from Agkistrodon piscivorus piscivorus or Naja melanoleuca of the present invention can improve, alleviate, or treat symptoms of rheumatoid arthritis, which is a kind of autoimmune diseases, and thus will be able to be widely used in the development of therapeutic agents for various autoimmune diseases including rheumatoid arthritis.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 17, 2022
    Applicant: DNBIO Pharm, Inc.
    Inventor: Seong Hyang Sohn
  • Patent number: 11492357
    Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 8, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: In Hwan Bae, Seung Hyun Jung, Young Gil Ahn, Kwee Hyun Suh
  • Patent number: 11484511
    Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 1, 2022
    Assignee: KOREA UNITED PHARM, INC.
    Inventors: Keon Wook Kang, Sung Baek Jeong